Additionally, the Cur treatment changed the methylation status of the NRF2 gene’s CpG promoter region, causing NRF2 and its target gene, NQO-1, to be expressed again and thus having a chemopreventive impact on prostate cancer [44]. This evidence concerns the gene NQO1 and Familial prostate cancer.